NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD
  • XY Feed
  • 24-HOUR Pass ↗
  • Push Notifications
Sign in Subscribe

Ligand Buys Xoma for $740M, Doubling Its Drug Royalty Portfolio

Ligand buys Xoma for $740M cash, boosting its drug royalty portfolio to 200+ medicines and spreading investment risk.

Ligand Buys Xoma for $740M, Doubling Its Drug Royalty Portfolio
XOMA Royalty Portfolio
Already have an account? Sign in.
04/27/2026 · 6:50 AM
XOMA
/ Don’t stop at just one post.

Related↓

Wells Fargo Upgrades GLUE, Jefferies Downgrades GBIO
12/16/2025 · 6:42 AM

Wells Fargo Upgrades GLUE, Jefferies Downgrades GBIO

Wells Fargo upgrades Monte Rosa Therapeutics on 2026 catalysts, while Jefferies downgrades Generation Bio due to its pending acquisition by Xoma.

/ Subscriber only
/ Read more

Feed↓

Google and Unity team up on AI tools that turn a text prompt into a playable game
10/07/2026 · 8:30 AM

Google and Unity team up on AI tools that turn a text prompt into a playable game

Roblox and Meta already offer similar tools to huge audiences.

/ Subscriber only
Micron’s Taiwan union votes to authorize strike over profit-sharing dispute
Featured/ 10/07/2026 · 8:06 AM

Micron’s Taiwan union votes to authorize strike over profit-sharing dispute

Micron’s Taoyuan union voted 99% to authorize a strike over profit-sharing. No date is set. Taiwan makes key DRAM and HBM chips.

/ Subscriber only
Sigma Lithium restarts Brazil mine after appeals court restores licenses, but community case remains open
10/07/2026 · 7:48 AM

Sigma Lithium restarts Brazil mine after appeals court restores licenses, but community case remains open

Sigma Lithium is mining again in Brazil after an appeals ruling. The 2027 output goal remains, while the expansion license stays on hold.

/ Subscriber only
Explore
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD
  • XY Feed
  • 24-HOUR Pass ↗
  • Push Notifications
More
  • Sign up
  • Sign in
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Terms/Privacy
  • UP↑
Get alerts

Be the first to know when deals break, stocks move, or biotech headlines hit.

Email address Subscribe
DON'T FALL BEHIND. ©2026
For informational purposes only. Not financial advice.
NOTRELOAD AI